Clinical trial · Interventional
Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
NCT00832689CI-TRIAL-00004608completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irinotecan and Gemcitabine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Irinotecan and Gemcitabine
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed inoperable biliary tract cancer * Age: 18 \~75 years old * Performance status: ECOG 0-2 * Hematopoietic: * Granulocyte count at least 1,500/mm3 * Platelet count at least 100,000/mm3 * Hepatic: * Bilirubin No greater than 2 fold the upper normal limit * AST/ALT : No greater than 3 fold the upper normal limit * Renal: * Creatinine - no greater than 1.5 mg/dL * Not pregnant * No other serious medical or psychiatric illness that would preclude giving informed consent or limit * No prior chemotherapy within 6 months * No other concurrent anticancer radiotherapy within 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.